18F-FDG PET/CT在鉴别不明原因发热病因中成人斯蒂尔病与淋巴瘤的价值

The value of 18F-FDG PET/CT imaging in differentiating adult-onset Still’s disease from lymphoma in the etiology of fever of unknown origin

  • 摘要:
    目的 探讨18F-氟脱氧葡萄糖(FDG)PET/CT在鉴别不明原因发热(FUO)病因中成人斯蒂尔病(AOSD)和淋巴瘤的影像特征及其诊断价值。
    方法 回顾性分析2016年12月至2018年12月在上海交通大学医学院附属瑞金医院以FUO为临床诊断行18F-FDG PET/CT显像的患者295例其中男性103例、女性192例,年龄(42.9±16.1)岁,筛选出AOSD患者69例、淋巴瘤患者36例。比较这两类患者在18F-FDG PET/CT图像上骨髓、脾脏、淋巴结等的代谢参数差异。组间比较采用卡方检验或独立样本t检验。
    结果 AOSD患者骨髓的18F-FDG高代谢发生率62.3%(43/69)对16.7%(6/36),χ2=28.4,P<0.001及最大标准摄取值(SUVmax)(5.5±1.8 对 4.2±1.2,t=5.1,P<0.001)均高于淋巴瘤患者。AOSD患者脾肿大发生率虽然低于淋巴瘤患者37.7%(26/69)对61.1%(22/36),χ2=6.3,P=0.011,但其脾脏SUVmax与淋巴瘤患者的差异无统计学意义(4.3±1.7 对 4.1±2.6,t=0.9,P=0.344)。AOSD患者淋巴结SUVmax(6.2±5.7 对10.9±8.8,t=−3.1,P=0.003)、总病灶代谢体积总MLV:(33.5±49.2) cm3对(80.3±399.2) cm3t=−4.9,P<0.001及总病灶糖酵解总量总TLG:(167.0±544.6) g 对(1304.0±3534.5) g,t=−4.3,P<0.001均低于淋巴瘤患者。
    结论 18F-FDG PET/CT可通过骨髓高代谢发生率和SUVmax、脾肿大的发生率、高代谢淋巴结的总MLV和总TLG等特征辅助鉴别FUO病因中的AOSD与淋巴瘤。

     

    Abstract:
    Objective To investigate the imaging features and diagnostic value of 18F-fluorodeoxyglucose (FDG) PET/CT in differentiating adult-onset Still’s disease (AOSD) from lymphoma in patients with fever of unknown origin (FUO).
    Methods A retrospective analysis was conducted on 295 patients (103 males, 192 females; mean age 42.9±16.1 years) who underwent 18F-FDG PET/CT for FUO at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, between December 2016 and December 2018. 69 AOSD patients and 36 lymphoma patients were included. Metabolic parameters of bone marrow, spleen, and lymph nodes on 18F-FDG PET/CT were compared between the two groups using chi-square tests or independent-sample t-tests.
    Results The incidence of 18F-FDG hypermetabolism in bone marrow 62.3% (43/69) vs. 16.7% (6/36), χ2=28.4, P<0.001 and maximum standardized uptake value (SUVmax) (5.5±1.8 vs. 4.2±1.2, t=5.1, P<0.001) were significantly higher in AOSD patients than in lymphoma patients. Although the incidence of splenomegaly was lower in AOSD patients than in lymphoma patients 37.7% (26/69) vs. 61.1% (22/36), χ2=6.3, P=0.011, there was no significant difference in spleen SUVmax between the two groups (4.3±1.7 vs. 4.1±2.6, t=0.9, P=0.344). AOSD patients exhibited lower lymph node SUVmax (6.2±5.7 vs. 10.9±8.8, t=−3.1, P=0.003), total metabolic lesion volume (total MLV: (33.5±49.2) cm3 vs. (80.3±399.2) cm3, t=−4.9, P<0.001), and total lesion glycolysis (total TLG: (167.0±544.6) g vs. (1304.0±3534.5) g, t=−4.3, P<0.001) compared to lymphoma patients.
    Conclusions 18F-FDG PET/CT can assist in differentiating AOSD from lymphoma as causes of FUO based on differences in features such as the incidence of bone marrow hypermetabolism, the incidence of splenomegaly, and the total metabolic lesion volume (MLV) and total lesion glycolysis (TLG) of hypermetabolic lymph nodes.

     

/

返回文章
返回